Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.

Journal of biomolecular structure & dynamics - 1 Jan 2023

Samad Abdus, Khurshid Beenish, Mahmood Arif, Rehman Ashfaq Ur, Khalid Asaad, Abdalla Ashraf N, Algarni Alanood S, Wadood Abdul

Abstract excerpt

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) serves as a molecular switch, cycling between guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound states. KRAS modulates numerous signal transduction pathways including the conventional RAF-MEK-ERK pathway. Mutations in the RAS genes have been linked to the formation of malignant tumors. Human malignancies typically show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutagenesis
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 37010994
DOI: 10.1080/07391102.2023.2192298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.PMID 37010994Read ↗

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read ↗

In-silico design of peptide inhibitors of K-Ras target in cancer disease.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

Structure-Based Discovery of Active Pan-KRas Inhibitors Targeting G12D Mutants by Enhanced Sampling Simulations.Semantic proximity Read ↗

KRAS G12D can be targeted by potent salt-bridge forming inhibitorsSemantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex.Semantic proximity Read ↗

Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.Semantic proximity Read ↗

Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.